Cue Biopharma, Inc.
CUE · XNASCIK 1645460fmd_0Z3N0S0VX7TGYKTM859D3G90VGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Jun 30, 2026, 38 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 1 | 3 | 3 | 15 | 1 | 5 | 9 | 27 |
| Rental revenue | – | – | – | – | 0 | 0 | 0 | – | – |
| Net interest income | – | – | – | – | 0 | (1) | (1) | (1) | (0) |
| Research and development | 19 | 29 | 27 | 34 | 41 | 39 | 41 | 36 | 38 |
| Total operating expenses | 23 | 40 | 40 | 48 | 59 | 54 | 58 | 51 | 54 |
| Operating income | (23) | (39) | (37) | (45) | (44) | (53) | (52) | (42) | (27) |
| Interest expense | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Income before taxes | (23) | (38) | (36) | (45) | (44) | (53) | – | – | – |
| Income tax expense | – | 1 | 0 | 0 | 0 | 0 | – | 0 | 1 |
| Net income from continuing operations | – | (39) | (37) | (45) | (44) | (53) | – | – | – |
| Net income | (23) | (39) | (37) | (45) | (44) | (53) | (51) | (41) | (27) |